{"entity":{"type":"insider","cik":"0001661908","url":"/insider/0001661908","json_url":"/insider/0001661908.json","name":"Sigal Charles Elliott","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":5,"first":"2016-05-18","last":"2023-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Sigal Charles Elliott","source":"filing","n_filings":5,"first_seen":"2016-05-18","last_seen":"2023-03-02"}],"transactions":[{"id":7949687,"accession":"0001209191-23-014673","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-014673","line_url":"/filing/0001209191-23-014673#line-1","is_derivative":false,"issuer_cik":"0001661908","issuer_name":"Vir Biotechnology, Inc.","issuer_ticker":"VIR","issuer_name_source":null,"issuer_url":"/issuer/0001661908","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":22.7262,"price_display":"22.73","price_state":"stated","total_value":56815.5,"total_display":"56,815.50","total_whole":"56,816","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-02","scope":"insider"},{"id":8362642,"accession":"0001209191-23-002507","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-002507","line_url":"/filing/0001209191-23-002507#line-1","is_derivative":false,"issuer_cik":"0001661908","issuer_name":"Vir Biotechnology, Inc.","issuer_ticker":"VIR","issuer_name_source":null,"issuer_url":"/issuer/0001661908","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":24.9582,"price_display":"24.96","price_state":"stated","total_value":62395.5,"total_display":"62,395.50","total_whole":"62,396","shares_owned_after":7500.0,"shares_owned_after_display":"7,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-05","filed_date":"2023-01-09","scope":"insider"},{"id":8362604,"accession":"0001209191-23-001932","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-001932","line_url":"/filing/0001209191-23-001932#line-2","is_derivative":false,"issuer_cik":"0001661908","issuer_name":"Vir Biotechnology, Inc.","issuer_ticker":"VIR","issuer_name_source":null,"issuer_url":"/issuer/0001661908","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":25.2545,"price_display":"25.25","price_state":"stated","total_value":63136.25,"total_display":"63,136.25","total_whole":"63,136","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-04","filed_date":"2023-01-05","scope":"insider"},{"id":8362599,"accession":"0001209191-23-001932","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-001932","line_url":"/filing/0001209191-23-001932#line-1","is_derivative":false,"issuer_cik":"0001661908","issuer_name":"Vir Biotechnology, Inc.","issuer_ticker":"VIR","issuer_name_source":null,"issuer_url":"/issuer/0001661908","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2500.0,"shares_display":"2,500","price_per_share":25.597,"price_display":"25.60","price_state":"stated","total_value":63992.5,"total_display":"63,992.50","total_whole":"63,993","shares_owned_after":2500.0,"shares_owned_after_display":"2,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-03","filed_date":"2023-01-05","scope":"insider"},{"id":3206960,"accession":"0001104659-16-122115","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-16-122115","line_url":"/filing/0001104659-16-122115#line-1","is_derivative":false,"issuer_cik":"0001621227","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001621227","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares with a nominal value of GBP0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":1.56,"price_display":"1.56","price_state":"stated","total_value":23400.0,"total_display":"23,400.00","total_whole":"23,400","shares_owned_after":314100.0,"shares_owned_after_display":"314,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-19","filed_date":"2016-05-19","scope":"insider"},{"id":2505864,"accession":"0001104659-16-121929","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-16-121929","line_url":"/filing/0001104659-16-121929#line-3","is_derivative":false,"issuer_cik":"0001621227","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001621227","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares with a nominal value of GBP0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":1.55,"price_display":"1.55","price_state":"stated","total_value":23250.0,"total_display":"23,250.00","total_whole":"23,250","shares_owned_after":299100.0,"shares_owned_after_display":"299,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-18","filed_date":"2016-05-18","scope":"insider"},{"id":2505860,"accession":"0001104659-16-121929","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-16-121929","line_url":"/filing/0001104659-16-121929#line-2","is_derivative":false,"issuer_cik":"0001621227","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001621227","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares with a nominal value of GBP0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":1.53,"price_display":"1.53","price_state":"stated","total_value":22950.0,"total_display":"22,950.00","total_whole":"22,950","shares_owned_after":284100.0,"shares_owned_after_display":"284,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-17","filed_date":"2016-05-18","scope":"insider"},{"id":2505857,"accession":"0001104659-16-121929","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-16-121929","line_url":"/filing/0001104659-16-121929#line-1","is_derivative":false,"issuer_cik":"0001621227","issuer_name":"Adaptimmune Therapeutics PLC","issuer_ticker":"ADAP","issuer_name_source":null,"issuer_url":"/issuer/0001621227","owner_cik":"0001661908","owner_name":"Sigal Charles Elliott","owner_display_name":"Sigal Charles Elliott","owner_url":"/insider/0001661908","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares with a nominal value of GBP0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":22500.0,"total_display":"22,500.00","total_whole":"22,500","shares_owned_after":269100.0,"shares_owned_after_display":"269,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-16","filed_date":"2016-05-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":8,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001706431","name":"Vir Biotechnology, Inc.","url":"/issuer/0001706431","role":"Director","n_filings":3,"first_seen":"2023-01-05","last_seen":"2023-03-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001621227","name":"Adaptimmune Therapeutics PLC","url":"/issuer/0001621227","role":"Director","n_filings":2,"first_seen":"2016-05-18","last_seen":"2016-05-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001661908","retrieved_at":"2026-08-25T16:26:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}